Efficacy and Safety of COVID-19 Treatments

Join us in enabling researchers to discover, access and analyse COVID-19 datasets to develop insights into the treatment of COVID-19

ICODA
International COVID-19
Data Alliance

We are inviting trialists to provide summary-level data from their COVID19 treatment trials

Use of data is strictly non-commercial

Who we are

The International COVID-19 Data Alliance (ICODA) aims to unite international health research data to accelerate discoveries that benefit everyone, everywhere, by reducing the harm of COVID-19 and enabling an efficient data response to future pandemics and other health challenges.

We are building a research ecosystem that provides datasets, secure workspaces and tools to harness the power of data at a global level to:

▶ Transform the way global health data is identified, accessed and used to yield scientifically credible results

▶ Accelerate the research community's ability to provide reliable answers to the most pressing scientific questions about COVID-19

ICODA has already received considerable support from pharmaceutical and academic partners who are making their data accessible through our platform.

We are now ready to increase the number of studies and researchers. Together we have the potential to build a global research community that will truly fast-track our impact on this pandemic.

"REMAP-CAP was designed as a worldwide trial to provide reliable information on potential treatments for COVID19. By participating in ICODA, the data generated from the trial can bring even greater insight in how to treat this disease."

Steve Webb Professor of Critical Care Research
Monash University

"The opportunities are unlimited to contribute to the treatment of COVID-19 and have a high impact on global health. We wanted to contribute all data possible to support this cause."

Ben Kramer VP of US Med Affairs
Immunology and Ophthalmology at Genentech

WHAT WE OFFER

We offer secure and controlled access (direct and federated) to both clinical trial and patient health data including:

Near-immediate access to results and data from the trials

Harmonisation of variable definitions and subgroup classifications from all trials using a **data dictionary**

A collaborative **COVID-19 Workbench** - a secure data research lab in a cloud environment with visual analytics & meta-analyses tools built on **FAIR** data principles

Strong and transparent governance including proportionate reviews of research proposals and outputs

A proven team with a global mission

ICODA complements and builds on existing data initiatives supporting researchers from around the world, and particularly from low and middle-income countries, to collaborate effectively as equal partners. We are a new entity with a highly skilled team and growing partner network.

How we are contributing to evaluating the efficacy and safety of COVID-19 treatments

Several thousand clinical COVID-19 trials are in progress globally. It is vital that the scientific community can consolidate knowledge across trials.

The summary level data from the most rigorous of these trials across industry, academia and government is being included in the ICODA COVID-19 Workbench. We have created a Data Dictionary that harmonises variable definitions and subgroup classifications from these trials. This allows interrogation of the benefit-risk profile of drugs across a number of safety and efficacy endpoints from multiple trials. Predefined subgroups can be better evaluated in pooled analyses across multiple trials, than unclear subgroup data from one trial. As a complement, ICODA has partnered with Certara to provide digitised summary level data from trials in the format they are reported in the public domain.

Accredited researchers are thus able to view data from individual trials in the context of other available trials. Our visual analytics and meta-analyses tools further enhance the researchers' ability to work quickly.

How you can help

We call on data partners to contribute their data, and join our community. With your support, we can strengthen our collective efforts and enable discoveries to help address this global challenge.

PROJECT LEADERSHIP

NÉVINE ZARIFFA
With 25 years in senior statistical roles, last as SVP of Biometrics at AstraZeneca, Névine is a recognised expert in data consortia and the executive sponsor for the project.

ANDREW MORRIS
As Director of Health Data Research UK, Andrew's vision has led to the development of a secure health data research infrastructure for the UK that is uniting, improving and using health data to enable discoveries that improve lives.

NEIL POSTLETHWAITE
After 23 years at IBM where he held a variety of technical, management and executive positions building infrastructure software and platforms, Neil joined ICODA as Technology Director.

JONAS HÄGGSTRÖM
As an experienced statistical leader in both the pharmaceutical sectors and global health, Jonas is chair of the ICODA Statistical Expert Group and VP of Global Health at Cytel.

CONTACT

To explore how we can work together, visit:

🌐 **www.icoda-research.org**

or contact:
Névine Zariffa
✉ **nevine.zariffa@hdruk.ac.uk**

Convened by

HDRUK
Health Data Research UK